The money spent on biopharma acquisitions in the second quarter looks huge, but most of the total is down to one deal.
2018 shaping up to be a bumper approval year, as Juno Therapeutics, Epizyme and Avexis line up to launch potential blockbusters.
Eagerly pursuing all the latest fads and trends.
Pharma companies have passed on in-licensing drugs such as Kite Pharma’s CAR-T therapy and Incyte’s IDO inhibitor. Do they know something?